Call to halt hydroxychloroquine prescribing, dispensing for COVID-19


alert warning

PSA strongly advises pharmacists to refuse dispensing of hydroxychloroquine outside of approved indications, and urges prescribers to stop writing prescriptions as a ‘just in case’ measure

Following President Trump’s announcement last week that hydroxychloroquine will be fast-tracked by the US Food and Drug Administration as a treatment for COVID-19 infection after showing “very encouraging early results”, Australian community pharmacies have seen unprecedented demand for the drug.

His announcement seems to be based on in-vitro evidence of activity against SARS coronavirus and, subsequent to that, the preliminary results from a small French study showing that the combination of hydroxychloroquine and azithromycin reduced viral load in people with COVID-19 infection, pharmacy academics have pointed out.

The study upon which the US President’s announcement was made has received criticism, not because the treatment is, or might be, ineffective,  but because there is no way to draw solid conclusions about the clinical benefits of this agent, based on this early data, they say, adding that a rigorous and sufficiently large randomised clinical trial is needed. 

The Pharmaceutical Society of Australia (PSA) has since heard from Australian pharmacies that they have been receiving prescriptions from doctors prescribing for other doctors and their families, as well as dentists prescribing to the community and their families, and non-medical prescribers prescribing bulk amounts of the drug.

PSA national president Chris Freeman has provided “strong advice” to pharmacists “to refuse the dispensing of hydroxychloroquine if there is not a genuine need” at this point in time, until further advice is available.

“That need is for those indications for what it is approved for – inflammatory conditions or the suppression and treatment of malaria,” says Associate Professor Freeman.

The stock of this medication needs to be managed effectively and utilised for those who many genuinely need it.

A/Prof Freeman adds that if the medication does indeed have efficacy against COVID-19, then the medication needs to be prescribed and used judiciously.

“The current stock of hydroxychloroquine needs to be managed sensibly, it needs to be available for those who are currently being prescribed this medicine, and it may also be needed for treatment of COVID-19 in the future,” he says.

A/Prof Freeman urges pharmacists to manage their existing stock of hydroxychloroquine sensibly, ensuring those who are currently prescribed the medicine have an existing supply.

PSA also urges prescribers not to write prescriptions for this medicine as a ‘just in case’ measure, and reiterates that pharmacists should refuse supply of hydroxychloroquine outside of the indications at this point in time.

“While the data may not yet be clear, if hydroxychloroquine is shown to be effective for COVID-19, we want every dose available to treat those who may require it,” A/Prof Freeman says.

PSA is currently working with the TGA and the Minister for Health regarding appropriate management of national stockpiles and medicines stock.

Previous ‘Women who come into your pharmacy may not have anywhere to go.’
Next Leading tech company highlights surge in meds orders

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

3 Comments

  1. Karalyn Huxhagen
    24/03/2020

    Sadly the horse has already bolted and there is no Hydroxychloroquine available for those patients who have been stabilised on this drug for some time.
    In my region sending them back to their rheumatologist for a different medication is not an option. We have NIL rheumatologists seeing public patients.
    The government under TGA needs to invoke a supply chain for this medication ASAP from countries that use it routinely for other indications and who produce large quantities of this medication eg India.
    Border and country restrictions are not supposed to hamper medicine and freight – we know they are- Australian patients with inflammatory disease deserve immediate action by TGA to push for import of this vital medicine.

  2. Totally agree – this medication – should be in the hands of ID Physicians at a Hospital for patients with proven Covid19 – not Rxed for just in case – shades of toilet paper panic buying there. If it works then it could be the difference between life & death – but as we keep hearing still unproven. Hope it does work … we will find out no doubt what does & doesn’t or ….if anything at all works in the coming weeks.

    • Ron Batagol
      24/03/2020

      Agreed, don’t use prophylactically “just in case” – for no other reason than the risks that exist in its use, of the occurrence of severe retinal toxicity and other side-effects!!!

Leave a reply